Design, Synthesis, and Antirheumatoid Arthritis Mechanism of TLR4 Inhibitors

Area of Science:

• Medicinal Chemistry
• Immunology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation.
• Current RA treatments have limitations, necessitating the development of novel therapeutic agents.
• Targeting inflammatory pathways like Toll-like receptor 4 (TLR4) signaling is a key strategy for RA treatment.

Purpose of the Study:

• To synthesize and evaluate novel carbonyl compounds for anti-inflammatory activity.
• To identify potent compounds for the treatment of rheumatoid arthritis.
• To elucidate the preliminary mechanism of action of the most active compound.

Main Methods:

• Synthesis of 12 carbonyl compounds.
• In vitro evaluation of lipopolysaccharide (LPS)-induced inhibition in RAW264.7 cells.
• Assessment of cytokine release (TNF-α, IL-1β, IL-6).
• In vivo testing using a collagen-induced arthritis (CIA) mouse model.
• Mechanism studies involving protein and gene expression analysis (TLR4, TNF-α, NF-κB).
• Molecular docking simulations to assess TLR4 receptor affinity.

Main Results:

• Compound 3k demonstrated significant inhibitory activity against LPS-induced RAW264.7 cells with an IC50 of 1.02 ± 0.08 μM.
• Compound 3k markedly suppressed the release of pro-inflammatory cytokines TNF-α, IL-1β, and IL-6.
• In the CIA model, compound 3k exhibited therapeutic effects comparable to methotrexate.
• Preliminary studies indicated compound 3k modulates TLR4, TNF-α, and NF-κB expression and related inflammatory genes.
• Molecular docking revealed favorable binding affinity of compound 3k to the TLR4 receptor.

Conclusions:

• Compound 3k is a potent inhibitor of inflammation in vitro and in vivo.
• Compound 3k exerts its anti-inflammatory effects potentially through the TLR4/NF-κB signaling pathway.
• Compound 3k represents a promising lead candidate for the development of novel rheumatoid arthritis therapeutics.